Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-UK will have public guidelines for Brexit talks before triggering Article 50 - minister

Mon, 12th Sep 2016 18:55

(Recasts, adds quotes, context)

By William James

LONDON, Sept 12 (Reuters) - Britain will make public itsguidelines for talks on leaving the European Union by the timeit triggers the exit process, Brexit minister David Davis saidon Monday, in the first indication of when Britons will find outwhat the government hopes to achieve in the talks.

Prime Minister Theresa May's government has warned it willreveal little about its strategy on key issues like immigrationand trade as it prepares to negotiate Britain's exit from the EUfollowing the shock June 23 referendum vote to leave.

But Davis, head of the newly created Department for Exitingthe European Union, said the negotiating process itself wouldnot be a "black box" and that details would begin to emerge oncethe legal exit procedure, known as 'Article 50' began.

"It will start, I guess, at the point of triggering Article50. We will at that point have a some clear public negotiatingguidelines," David told a committee of lawmakers investigatingthe role of parliament in the Brexit process.

The government has been pressed for detailed answers on howit intends to enact the decision to quit the bloc by everyonefrom business leaders to foreign allies.

So far, it has revealed little.

"Before Article 50 is triggered there will be a ratherfrustrating time, because we won't be saying an awful lot,"Davis said. He said giving a running commentary on the talkswould undermine Britain's negotiating stance.

Separately, finance minister Philip Hammond sought toaddress the concerns of businesses about Brexit, meeting withlarge exporters like Honda, Airbus andGlaxoSmithKline to tell them that trade with EU memberstates would be a priority in the exit talks.

FAST AND RESPONSIVE

Once the exit process has been started, Britain has aninitial two-year period to negotiate its departure. Davis saidthis time frame was possible, but would require the governmentto be "nimble, fast and responsive." The talks can be extendedif both parties agree.

Davis said parliament would be called upon to pass new lawsto enact the exit from the bloc. The government has previouslystated parliament did not need to approve the decision totrigger an exit.

He said the negotiating strategy would be drawn up byassessing feedback from other government departments which havebeen asked to consult with relevant parties on the opportunitiesbrought about by leaving, the risks of leaving, and bestpolicies to mitigate those risks.

"At that point, which is not yet, we will be doing somequite quantitative assessment of what we think the advantagesand disadvantages are," he said. "We need to take an empiricalapproach. The purpose of this is not to damage the nationalinterest or damage economic interest, it's just the reverse." (Additional reporting by Estelle Shirbon and Elizabeth Piper;Editing by Hugh Lawson)

More News
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.